Kornimate/medical-research-clean huggingface dataset:
osteoporosis in children with all

Conditions: Leukemia, Lymphocytic, Acute, L1

Summary: hypothesis: pediatric patients with acute lymphoblastic leukemia, treated with chronic glucocorticoids as a part of the leukemia treatment protocol, will have an increased incidence and severity of osteoporosis.

osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration of bone tissue. osteoporosis is a devastating disorder with significant physical, psychosocial and financial consequences. intensive chemotherapy and radiotherapy have led to significant improvements in long term, disease-free survival of children with malignancies. unfortunately, there are many deleterious side effects associated with this therapy. little is known about the longitudinal changes in bone mass accumulation and bone metabolism in these patients. the purpose of this study is to evaluate the timing and severity of changes in bone mineral metabolism for children treated for childhood leukemia. data will be used to establish treatment protocols with the goal of preventing severe fractures and pain in the acute treatment stage and severe osteoporosis and related pathology in the chronic stage.

Eligibility criteria:
inclusion criteria: * all pediatric patients with a new diagnosis of all between ages 4-18 * patients who are expected to receive glucocorticoids as part of the leukemia treatment protocol * bone density measurements must be performed at the diagnosis visit or maximally within 48 hours after the first dose of glucocorticoids exclusion criteria: * patients under 4 years of age are excluded due to lack of age appropriate standards for bone mineral density * glucocorticoid therapy of at least one month or longer within the six months prior to dx * history of connective tissue or musculoskeletal disorders * biphosphonate therapy within the past 6 months * acute renal failure * serum creatinine equal to or higher than 4.5mg/dl * positive serum pregnancy test in adolescent females

Keywords: osteoporosis childhood acute lymphoblastic leukemia
the effect of osa on pregnancy and fetal outcomes

Conditions: Pregnancy; Obstructive Sleep Apnea

Summary: this cohort study aims to investigate the impact of obstructive sleep apnea hypopnea syndrome (osa) on pregnancy and fetal outcomes. the hypothesis posits that osa may aggravate pregnancy complications, elevate the risk of adverse pregnancy outcomes, and potentially impact fetal development.


Eligibility criteria:
inclusion criteria: * pregnant women with a confirmed diagnosis of osa based on polysomnography or other validated sleep monitoring techniques. * pregnant women who are willing to participate in the study and provide informed consent. exclusion criteria: * pregnant women with other respiratory or sleep disorders that may confound the diagnosis of osa. * pregnant women with severe comorbidities or medical conditions that may significantly impact pregnancy outcomes. * pregnant women who have undergone surgical treatment for chronic tonsillitis or osa during the study period. * pregnant women who refuse to participate in the study or are unable to provide informed consent.
oral acetazolamide, brimonidine tartarate, and anterior chamber paracentesis for ocular hypertension control after intravitreal bevacizumab

Conditions: Age Related Macular Degeneration; Diabetic Retinopathy

Summary: the purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.


Eligibility criteria:
inclusion criteria: * diagnosis of age related macular disease or diabetic retinopathy * able and willing to provide informed consent exclusion criteria: * history of ocular hypertension or glaucoma * high myopes (\> 6 spherical diopters) * high hyperopes (\> 4 spherical diopters) * pulmonary disease * renal disease * known allergy to any component of the study drug * myocardial infarction, transient ischemic attack within 4 months prior to randomization or any contraindication for bevacizumab use

Keywords: intraocular pressure bevacizumab acetazolamide brimonidine anterior chamber paracentesis
endorphin at labor pain and acupressure

Conditions: Labor Pain

Summary: this study was performed to determine the impact of different acupressure procedures, performed on women's hands during labor, on endorphin levels and labor pain perception. the sample consisted of 140 pregnant women. the study was conducted with three experimental groups and one control group, each including 35 pregnant women. conventional acupressure and warm and cold acupressure procedures were performed on the large intestinal 4 energy meridian zone acupressure point of the experimental group. no procedures were performed on the women in the control group. data were collected using a "personal information form", "labor intervention follow-up form", "visual analog scale" and "verbal category scale". the comparison between the experimental and control groups indicated that the conventional acupressure procedure was effective in reducing labor pain and that the warm acupressure procedure increased endorphin levels.


Eligibility criteria:
inclusion criteria: * being a primipara * having intact membranes * no skin diseases (such as urticaria...), * no use of narcotic drugs * having a term pregnancy * having a single fetus at vertex position * planning to have vaginal delivery * having contractions and ongoing regular augmentation * having recent augmentation starting periods * being in the latent phase (0-3 cm dilatation) * having no history of high-risk pregnancy * not using analgesic drugs to reduce pain during delivery * having no systemic and neurologic diseases * having no contraction anomaly (hypotonic or hypertonic contractions) exclusion criteria: having any of the above criteria. -

Keywords: acupressure labor pain midwifery pregnant women endorphins warm acupressure cold acupressure
study to evaluate effectiveness and safety in subjects with moderate to severe psoriasis

Conditions: Psoriasis

Summary: a study to evaluate efficacy and safety in subjects with moderate to severe psoriasis treated with bms-986165


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * male and female, ages 18 to 70 years * diagnosis of plaque psoriasis for 6 months * women of childbearing potential (wocbp) must have a negative serum or urine pregnancy test, must not be pregnant, lactating, breastfeeding or planning pregnancy * males who are sexually active with wocbp must agree to follow instructions for method(s) of contraception for the duration of treatment plus 5 half-lives of the study drug plus 90 days. exclusion criteria: * any significant acute or chronic medical illness * blood transfusion within 4 weeks of study drug administration * inability to tolerate oral medication * positive hepatitis-b (hbv) surface antigen * positive hepatitis-c (hcv) antibody * any history or risk for tuberculosis (tb) * any major illness/condition or evidence of an unstable clinical condition * chest x-ray findings suspicious of infection at screening * has received ustekinumab, secukinumab or ixekizumab within 6 months of first administration of study medication * has received anti-tumor necrosis factor (tnf) inhibitor(s) within 2 months of first administration of study medication * has received rituximab within 6 months of first administration of study medication * topical medications/treatments for psoriasis within 2 weeks of the first administration of any study medication * any systemic medications/treatments for psoriasis within 4 weeks of the first administration of any study medication other protocol defined inclusion/exclusion criteria could apply
antimicrobial photodynamic therapy in treatment of aggressive periodontitis (stage iii, grade c periodontitis)

Conditions: Aggressive Periodontitis

Summary: treatment of aggressive periodontitis (stage iii, grade c periodontitis) represents a big challenge. the aim of the study was to compare the long-term results of antimicrobial photodynamic therapy (apdt) and antibiotic therapy as an adjunct to conventional non-surgical therapy in patients with aggressive periodontitis. clinical parameters of probing depth, clinical attachment level and bleeding on probing (bop) were assessed at baseline, 3, 6, 9 and 12 months after treatment.

background: treatment of aggressive periodontitis (stage iii, grade c periodontitis) represents a big challenge. the aim of the study was to compare the long-term results of antimicrobial photodynamic therapy (apdt) and antibiotic therapy as an adjunct to conventional non-surgical therapy in patients with aggressive periodontitis. materials and methods: twenty subjects with untreated aggressive periodontitis (stage iii, grade c periodontitis) were divided into two groups: the test group (tg) received non-surgical therapy and two sessions of apdt using a laser (helbo theralite laser) with a wavelength of 670nm associated with helbo blue photosensitizer, and the control group (cg) received non-surgical therapy and antibiotics (amoxicillin 500mg and metronidazole 400mg, 7 days). clinical parameters of probing depth, clinical attachment level and bleeding on probing (bop) were assessed at baseline, 3, 6, 9 and 12 months after treatment.

Eligibility criteria:
inclusion criteria: * aggressive periodontitis (stage iii, grade c periodontitis) * nonsmokers * at least 20 teeth in oral cavity * systemically healthy exclusion criteria: * any previous periodontal treatment * smoking * pregnancy * ingestion of systemic antibiotics within three months before therapy

Keywords: photodynamic therapy antibiotic therapy
french observatory on the management of cardiogenic shock in 2016

Conditions: Shock, Cardiogenic

Summary: cardiogenic shock (cs) is defined as an organ hypoperfusion secondary to low cardiac output. catches diagnostic management, and therapeutic monitoring of these patients remain highly variable from one center to another and even from one doctor to another within the same team. the management protocols are often not standardized or non-existent. it appears therefore necessary to make an inventory of the management practices of the cs in france in 2016, prerequisite to a common work of standardization of practices and the creation of specialized networks to support these complex patients.

the observatory frenshock proposes to set up a cohort of 500 patients recruited prospectively over a period of 6 months. patients will be followed up at 1 month and 1 year patients should have agreed to participate in the observatory, knowing that participation or refusal to participate will not alter the therapeutic attitude of the physician responsible for the patient. the study of phenotypic characteristics will not change the therapeutic approach of the medical teams.

Eligibility criteria:
inclusion criteria: * informed consent * cardiogenic shock authenticated by the existence of at least one positive test for each of the following three parts: (a) low cardiac output (1 criterion necessary and sufficient): * clinic: sbp \ 90 mmhg * echocardiography: ic \<2.2l / min / m2 and / or lvef \<30% * hemodynamics by swan ganz catheterization or right: ic 2.2 l / min / m2 (b) elevation of pulmonary pressure / left surcharge (1 criterion necessary and sufficient): * clinical (ivd and abortion); * radiological (surcharge on rt or chest ct); * organic (ntprobnp\> 900pg / ml or bnp\> 400pg / ml); * echocardiography (e / a\> 2 if lvef \ 13 if normal lvef, or paps\> 35mmhg and / or tde \ 30ms and / or e / 2 vp≥ , 5); * right swan ganz catheterization or (pulmonary capillary pressures\> 15mmhg and / or mpap\> 25mmhg) (c) organs malperfusion (1 criterion necessary and sufficient): * clinic: oliguria \<30ml / kg / h, mottling, consciousness disorders) * organic: arterial lactate\> 2 mmol / l, liver failure, kidney failure exclusion criteria: * final diagnosis retained other than cardiogenic shock * cardiac arrest without spontaneous activity in the hospital management * post-cardiotomy cardiogenic shock * deprived of liberty patient * refusal or lack of consent

Keywords: cardiogenic shock observatory
neurophysiological characteristics of subthalamic deep-brain stimulation (stn-dbs)

Conditions: Parkinson Disease; Dystonia

Summary: the intraoperative neuroelectrophysiological signals were collected from patients undergoing stn-dbs under general anesthesia in the neurosurgery department of wuhan union hospital, and their preoperative conditions and postoperative efficacy will be evaluated.

the intraoperative neuroelectrophysiological signals were collected from patients undergoing stn-dbs under general anesthesia in the neurosurgery department of wuhan union hospital, and their preoperative conditions and postoperative efficacy will be evaluated. the intraoperative neuroelectrophysiological signals would be analyzed.

Eligibility criteria:
inclusion criteria: 1. patients underwentstn-dbs in neurosurgery department of wuhan union hospital. 2. patients with parkinson's disease or dystonia. exclusion criteria: 1.patients without enough follow-up length.

Keywords: parkinson disease dystonia deep brain stimultation neurophysiological characteristics
an open-label study of the effects of elagolix in adult premenopausal females

Conditions: Folliculogenesis

Summary: this is an open-label phase 1 study in healthy premenopausal females evaluating the effects of different dosing regimens of elagolix on ovarian activity, ovulation, and ovarian reserve and to assess the effect of elagolix on selected endocrine/hormone levels.

this is an open-label, multiple-dose, phase 1 study in premenopausal subjects aged 18 years to 40 years, with a history of regular menstrual cycles (24 to 32 days long) and no evidence of significant gynecological disorders. the objective of the study is to determine the effects of different dosing regimens of elagolix on ovulation, ovarian activity, and ovarian reserve. the study consists of 3 periods: a screening period of up to 50 days prior to the first dose, a treatment period of 3 months duration (cycles 1-3), and a follow-up period of up to 60 days. during the screening and treatment menstrual cycles, serial transvaginal ultrasounds and determination of serum levels of luteinizing hormone, follicle-stimulating hormone, estradiol, progesterone, and inhibin b will be performed three times weekly. subjects will maintain a daily diary of uterine bleeding. pregnancy testing will be performed frequently throughout the study. subjects will be required to use nonhormonal dual contraception consistently during the study, and will be counseled on appropriate and effective forms of birth control to promote pregnancy prevention.

Eligibility criteria:
inclusion criteria: - premenopausal female, between 18 and 40 years of age, inclusive - history of regular menstrual cycles - endocrine and ultrasonographic evidence of ovulation and normal ovulatory cycle during the screening period - follicle-stimulating hormone level of \<35 miu/ml - agrees to use required birth control methods during the entire length of participation in the study exclusion criteria: - screening ultrasound results show a clinically significant gynecological disorder - surgical history of hysterectomy without oophorectomy, unilateral or bilateral oophorectomy, removal of ovarian cysts - less than 6 months postpartum or post-lactation at the start of study drug dosing - pregnant or breast feeding or is planning a pregnancy within the next 12 months - testosterone concentration \>120 ng/dl at screening

Keywords: healthy volunteers elagolix endometriosis ovarian reserve gonadotropin-releasing hormone antagonist ovulation ovarian activity
prevalence of hpv (human papilloma virus) and hpv vaccination among victims of sexual violence

Conditions: Human Papilloma Virus; Sexual Assault; Sex Abuse

Summary: by a prospective single center cohort study in the sexual assault care center (sacc) of the chu (centre hospitalier universitaire) saint pierre in brussels, we would like to : * to evaluate the prevalence of hpv infections in the population of women over 15 years old admitted for rape * to determine the prevalence of hpv and the clearance in hpv-vaccinated and unvaccinated patients

the investigators will conduct a prospective single center cohort study in the sacc of the chu saint pierre in brussels. population: the investigators will include all women over 15 years admitted to the sacc of brussels between 5/02/2024 and 05/02/2024 for rape (vaginal and/or oral and/or anal penetration) after signing the consent. pcr (polymerase chain reaction) smears for hpv testing will be performed after obtaining consent from the victims. these smears will be performed at the oral, vaginal and anal site. the smears will be taken either by the patient or by the legal nurse, according to the victim's wishes. ideally, 3 smears should be taken : oral, vaginal and anal. it will be carried out at the same time as all other sexual transmitted deseases tests and should therefore not be perceived as more invasive or time-consuming. these smears will be performed two times: at the first visit of the patients to the sacc and after 12 at 18 months. appointment reminders will be sent by phone contact. the test used is a swab analyzed by pcr via the aml laboratory. they confirmed that this is the most sensitive method for detecting hpv in vaginal and anal areas, and probably also in oral areas. the hpvs obtained via pcr are: 16 18 45 33 58 31 52 35 59 39 51 56 68 67 53 66 6 and 11. results will therefore be classified as low-risk, high-risk or hpv-negative. patients will be notified if a high-risk hpv test is detected, and treatment will be offered depending on the type of follow-up required according to the international recommendations. outcomes: * define high-risk hpv carriage in the sacc population. * define the proportion of sacc patients vaccinated for hpv. secondary objectives: * to characterize hpv subtypes, according to the type of assault and infected sites (vaginal-cervical, anal, oral). * to determine the prevalence of hpv and the clearance in hpv-vaccinated and unvaccinated patients (itself assessed by the presence of one type of hpv in the first smear and its absence in the followed smears).

Eligibility criteria:
inclusion criteria: * women over 15 years admitted for rape speaking in french, dutch or english (and therefore able to sign an inform consent in french, dutch or english) exclusion criteria: * tourist or other people who will not in belgium one year after their first test
preparation for medical and surgical procedures in oncogeriatry.

Conditions: Geriatric Oncology

Summary: surgical management is one of the most frequently used interventions in the treatment of many cancers, but it can be associated with a high risk of postoperative complications. the maintenance and optimization of functional abilities before, during and after treatment are major for elderly cancer patients, as it is now well established that there is a link between the level of functional capacity and the occurrence of these complications. the scientific literature shows that the benefits of pre- and post-operative training programs, but these benefits only apply to a fraction of the patients adhering to the programs. the modalities of intervention (training load, follow-up, etc.) as well as patient involvement in these programs are major issues that need to be addressed to optimize their benefits. individualizing pre-habilitation, on the basis of the management of the training load, and therefore objective fatigue, would enable better patient adherence to the program, and optimize its benefits. in this context, the primecho project aims to individualize pre-habilitation in order to improve functional of patients in the pre-habilitation or accelerated recovery after surgery phase. the aim is for the patient to be in optimum physical condition at the time of the intervention or treatment.


Eligibility criteria:
inclusion criteria: * patient aged 70 or over * cancer patient with planned surgery, * mini mental state examination score greater than or equal to 24 (performed in advance by the geriatrician), * patient affiliated to or benefiting from a social security insurance * signed free and informed consent. exclusion criteria: * inability to walk or perform unsupervised exercises. * vulnerable people

Keywords: ederly cancer
comparison of safety and efficacy of four-point scleral intraocular lens fixation and yamane techniques

Conditions: Aphakia

Summary: comparison of safety and efficacy of two scleral fixation intraocular lens (iol) methods of four-point scleral fixation ( akreos ao60) and the yamane technique (acrysof ma60ac)

purpose of the study is to compare two methods of scleral fixation of iol: two-point fixation of acrysof ma60ac iol (alcon) using yamane technique and four-point fixation of the akreos ao60 iol (bausch \& lomb) using polypropylene suture. the investigators rated the bcva, refractive outcomes, intraocular pressure, and also determined intra- and postoperative complications.

Eligibility criteria:
inclusion criteria: * only adult men and women with aphakia without capsular support exclusion criteria: * fuchs' dystrophy * corneal haze or scarring * history of corneal transplantation * astigmatism of more than 2,0d * clinically active uveitis * advanced glaucoma * macular diseases that affect visual acuity (age-related macular degeneration, diabetic maculopathy)

Keywords: scleral fixation iol sutureless fixation iol four-point scleral fixation yamane technique aphakia
cryoablation vs lumpectomy in t1 breast cancers

Conditions: Breast Cancer; Breast Neoplasm

Summary: this trial studies the efficacy and safety of cryoablation in patients with low risk, early stage breast cancer. cryoablation is a method of killing a tumor by freezing it. the standard approach for patients with this kind of cancer is a lumpectomy. this study will review the safety of the cryoablation procedure initially, followed by comparing cryoablation to lumpectomy in order to see if the cryoablation results in better disease control, complication rates, and quality of life.


Eligibility criteria:
inclusion criteria: * diagnosis of invasive ductal carcinoma of the breast of luminal type a (er/pr positive, her-2 negative) that is grade 1 or 2 with intraductal component \<25%. must be t1n0m0 (2 cm or less). * oncotyping will be performed on t1b+allred\<6/8 and t1c tumors. oncotype score in this subset of patients must be \<26 to be included in the trial. * at least 50 years of age. * mass must be visible on ultrasound and \>5 mm from skin and chest wall muscles. * able to understand and willing to sign an irb-approved written informed consent document. exclusion criteria: * indication for neoadjuvant chemotherapy. * prior history of breast cancer. * breast augmentation. * allergy to local anesthetics. * pregnant or lactating. women of childbearing potential must have a negative pregnancy test within 14 days of study entry. * dcis present beyond the proposed ablation zone on mri, mammography, or ultrasound. * positive axillary lymph nodes as assessed by axillary ultrasound, axillary sampling, or axillary sentinel node procedure.

Keywords: breast cancer cryoablation lumpectomy